Value proposition

Developing tomorrow's cancer therapies. Today.

invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer.
We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials.
We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics.
Our highly motivated team of 35 people has deep expertise across the biotechnology value chain, with in-house expertise in R&D, clinical development, CMC, IP, scouting and more.
All of our approaches are designed with a single goal: To transform patients' lives, so that cancer doesn’t.

Biotech, Precision medicine, Cell therapy, Small molecule, Personalised medicine, Immunotherapy, Novel cancer therapies, Immuno-oncology, and Checkpoint inhibition